שולי רווח תפעולי Protalix (PLX)

Protalix BioTherapeutics is developing a plant-cell protein synthesis system for the treatment of rare pathologies. The operating margin trend shows that the current level is 29.80. High R&D potential and unique patents provide the company with a technological edge. The business is currently scaling sales of its approved enzyme drug through partnerships with pharma behemoths while introducing new molecules.
פילוחי מדדים ואנליטיקה של חברת Protalix BioTherapeutics, Inc. (PLX)

Operating margin measures the efficiency of the core business by determining the share of profit before taxes and interest relative to total revenue. This indicator allows for an assessment of internal process profitability and helps avoid overpaying for an asset. By analyzing the quarterly operating margin, an investor can gauge the stability of cash flows. For Protalix BioTherapeutics (PLX), this metric reflects a dependence on a single drug. A partnership with a global distributor helps stabilize margins within a single-product revenue structure.